CVS Health Financial Model
Health Insurance Company Financials Example (Free Excel Download)
CVS Health is a vertically integrated health solutions company that operates across the entire healthcare spectrum, providing health insurance, pharmacy benefit management, and retail pharmacy services.
professionals from Deloitte
Used by professionals from
About this model
This model evaluates CVS Health's sum-of-the-parts equity valuation to determine whether the turnaround in Medicare Advantage margins and the stabilisation of the retail pharmacy footprint can offset pharmacy benefit manager pricing pressures and drive sustainable free cash flow generation.
CVS Health is a vertically integrated health solutions company that operates across the entire healthcare spectrum, providing health insurance, pharmacy benefit management, and retail pharmacy services. The company aims to control healthcare costs and improve patient outcomes by directing patients through its owned assets, from primary care clinics to prescription fulfillment.
Business segments include:
- Health Services (approx. 40% of revenue): Includes the CVS Caremark pharmacy benefit manager (PBM) and healthcare delivery assets such as Oak Street Health and Signify Health.
- Health Care Benefits (approx. 30% of revenue): Operates under the Aetna brand, providing traditional, voluntary, and consumer-directed health insurance products, including Medicare Advantage and Medicaid.
- Pharmacy & Consumer Wellness (approx. 30% of revenue): Comprises the retail pharmacy network, specialty pharmacy stores, and front-store general merchandise sales.
The business model is a highly integrated, high-volume, low-margin healthcare platform. CVS holds a dominant competitive position as the largest pharmacy chain and PBM in the United States, and it ranks as a top-three health insurer. Recent major events include the appointment of David Joyner as CEO in October 2024, a $5.7 billion goodwill impairment in 2025 related to the Health Care Delivery reporting unit, and the 2025 rollout of the "CVS CostVantage" cost-plus pharmacy pricing model.
The downloadable CVS Health financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsCVS Health financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $292.11B | $322.47B | $357.78B | $372.81B | $402.07B |
| Gross profit | $116.31B | $125.58B | $140.68B | $166.52B | $180.90B |
| Operating income | $13.31B | $7.95B | $13.74B | $8.52B | $4.66B |
| Net income | $8.00B | $4.31B | $8.34B | $4.61B | $1.77B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for CVS Health
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Health Care Benefits
- Segment name: Health Care Benefits
- Revenue driver formula: Total Medical Membership x Average Premium per Member per Month (PMPM) x 12
- Historical growth rate: 10% to 23% CAGR (heavily influenced by Medicare Advantage expansion)
- Key growth levers and headwinds: Medicare Advantage Star Ratings directly impact reimbursement rates. Membership growth in individual exchanges and commercial segments acts as a lever, while higher medical utilisation and Medicaid redeterminations serve as headwinds.
- Pricing dynamics: Highly regulated. Premiums are set annually based on actuarial estimates of medical costs.
- Revenue recognition notes: Premiums are recognised ratably over the coverage period.
- Seasonality: Q1 sees the highest enrollment influx, while Q4 typically experiences the highest medical costs as patients meet their deductibles.
Health Services
- Segment name: Health Services
- Revenue driver formula: Total Pharmacy Claims Processed x Average Revenue per Claim
- Historical growth rate: 4% to 7%
- Key growth levers and headwinds: Growth is driven by specialty pharmacy volume and the expansion of Oak Street Health clinics. Headwinds include client losses (such as the Centene contract) and intense legislative scrutiny over PBM pricing transparency.
- Pricing dynamics: Contractual pricing with health plans and employers, often involving complex rebate sharing mechanisms with drug manufacturers.
- Revenue recognition notes: Recognised when the claim is adjudicated and the prescription is dispensed.
- Seasonality: Relatively stable, though Q4 sees a slight uptick in prescription volumes.
Pharmacy & Consumer Wellness
- Segment name: Pharmacy & Consumer Wellness
- Revenue driver formula: (Prescriptions Filled x Average Price per Rx) + Front Store Revenue
- Historical growth rate: 3% to 5%
- Key growth levers and headwinds: Drug mix (branded versus generic) and vaccination volumes drive growth. Headwinds include retail theft, declining front-store foot traffic, and the closure of approximately 900 underperforming stores.
- Pricing dynamics: Transitioning to the CVS CostVantage model, which uses a transparent formula based on the cost of the drug, a set markup, and a flat dispensing fee.
- Revenue recognition notes: Recognised at the point of sale.
- Seasonality: Q4 is typically the strongest due to the cold and flu season and holiday front-store sales.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Health Care Costs (medical claims paid by Aetna), Pharmacy and Other COGS (cost of prescription drugs, PBM network costs, and front-store merchandise).
- Gross margin range: 14% to 16% consolidated.
- Key input costs and commodity exposures: Branded and generic drug acquisition costs, hospital and physician reimbursement rates.
- How COGS scales with revenue: Highly linear. The Medical Benefit Ratio (MBR) dictates that 85% to 89% of health insurance premiums are immediately paid out as medical costs.
Operating Expenses
- R&D: Not material for this company.
- SG&A: Store payroll, corporate overhead, IT infrastructure, and PBM administrative costs. Typically runs at 10% to 12% of revenue.
- Depreciation & Amortisation: Approximately 1.5% of revenue, heavily weighted towards amortisation of intangible assets from the Aetna and Caremark acquisitions.
- Stock-Based Compensation: Less than 0.5% of revenue.
- Restructuring / one-time charges: Frequent and massive. The company recorded a $5.7 billion goodwill impairment and $1.2 billion in legacy litigation charges in 2025.
Margin Profile
- Gross margin: 14% to 16%
- EBITDA margin: 4% to 6%
- Operating margin: 1% to 3% (GAAP, heavily distorted by impairments) or 4% to 5% (Adjusted)
- Net margin: 0.5% to 2.0%
- Margin trend: Compressing recently due to elevated medical utilisation in the Aetna business and PBM pricing pressures, with management targeting a recovery beginning in 2026.
Balance Sheet Structure
- Total assets: Approximately $240 billion to $250 billion.
- Key asset categories: Goodwill and intangible assets dominate the balance sheet due to a history of transformational acquisitions.
- Goodwill & intangibles as % of total assets: 45% to 50%.
- Working capital profile:
- Days Sales Outstanding (DSO): 20 to 25 days.
- Days Inventory Outstanding (DIO): 25 to 30 days.
- Days Payable Outstanding (DPO): 40 to 45 days.
- Net working capital as % of revenue: Negative 2% to negative 4%.
- Working capital dynamic: The company operates with negative net working capital, funding growth through high payables to drug manufacturers and deferred premium revenue.
- PP&E: Consists of retail store fixtures, clinic buildouts, and technology hardware. Useful lives range from 3 to 15 years.
- Right-of-use assets / operating leases: Highly material due to the massive retail footprint, typically representing $15 billion to $18 billion in assets.
Capital Expenditure & Investment
- Capex as % of revenue: 0.7% to 0.9% (very asset-light relative to revenue scale).
- Maintenance capex vs. growth capex: Approximately 60% maintenance (store refreshes, IT) and 40% growth (Oak Street Health clinic expansion, digital platform development).
- Major capex programmes underway: Expanding the primary care footprint and integrating technology systems across Aetna and Caremark.
- Capitalised software / development costs: Material component of total capex, reflecting the shift towards digital health solutions.
- M&A pattern: Historically a transformational acquirer (Caremark, Aetna) but recently shifted to multi-billion dollar bolt-ons (Oak Street Health, Signify Health).
Debt & Capital Structure
- Total debt: Approximately $60 billion to $65 billion.
- Debt/EBITDA ratio: Current leverage is around 3.5x, with a long-term target of 3.0x.
- Credit rating: BBB (S&P) / Baa2 (Moody's).
- Key debt instruments: Senior notes and a commercial paper programme used for working capital management.
- Maturity profile: Well-laddered, with $3 billion to $5 billion maturing annually over the next five years.
- Interest rate profile: Predominantly fixed-rate bonds, with a weighted average cost of debt around 4.5%.
- Share repurchase programme: Paused in 2024 and 2025 to prioritise debt paydown and absorb medical cost pressures.
- Dividend policy: $2.66 annual dividend per share, representing a yield of approximately 3.5% to 4.5% and a payout ratio of 35% to 40% of adjusted EPS.
Cash Flow Characteristics
- Operating cash flow conversion: 1.5x to 2.0x of GAAP Net Income (heavily skewed by massive non-cash D&A and impairment charges).
- Free cash flow margin: 1.5% to 2.5%.
- Major non-cash items: Depreciation, amortisation of acquired intangibles, and periodic goodwill impairments.
- Working capital cash flow impact: Generally a source of cash during periods of revenue growth due to the negative working capital cycle.
- Capex intensity: Very low, allowing for strong free cash flow generation despite thin operating margins.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are typically lower than the GAAP rate due to accelerated depreciation and the amortisation of goodwill for tax purposes in certain legacy acquisitions.
Sheet Structure
- Assumptions: Hardcoded drivers for segment growth, MBR, margins, and capital allocation.
- Summary: Dashboard displaying consolidated revenue, adjusted EPS, free cash flow, and valuation outputs.
- Segment Revenue & Gross Profit: Detailed build for Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness. Crucially, this sheet must include an "Intersegment Eliminations" section to reconcile gross segment revenues to consolidated net revenue.
- Operating Expenses: SG&A build, depreciation schedule, and a separate line for restructuring and impairment charges.
- Income Statement: Consolidated view from Revenue down to Net Income and Adjusted EPS.
- Balance Sheet: Assets, Liabilities, and Equity, highlighting the massive goodwill and operating lease liabilities.
- Cash Flow Statement: OCF, Capex, and Financing activities, bridging net income to the change in cash.
- Debt Schedule: Tranche-by-tranche breakdown of senior notes, commercial paper, and interest expense calculations.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, and terminal value assumptions.
Key Financial Relationships
- `Health Care Benefits Revenue = Medical Membership x Average Premium PMPM x 12`
- `Health Care Costs = Health Care Benefits Revenue x Medical Benefit Ratio (MBR)`
- `Health Services Revenue = Total Pharmacy Claims Processed x Average Revenue per Claim`
- `Pharmacy & Consumer Wellness Revenue = (Prescriptions Filled x Average Price per Rx) + Front Store Revenue`
- `Intersegment Eliminations = (Health Care Benefits payments to Health Services) + (Health Services payments to Pharmacy & Consumer Wellness)`
- `Consolidated Total Revenue = Health Care Benefits Revenue + Health Services Revenue + Pharmacy & Consumer Wellness Revenue + Intersegment Eliminations`
- `Consolidated Gross Profit = Consolidated Total Revenue - Health Care Costs - Pharmacy and Other COGS`
- `Adjusted Operating Income = GAAP Operating Income + Amortisation of Intangible Assets + Goodwill Impairments + Restructuring Charges`
- `Adjusted EPS = (Adjusted Operating Income - Interest Expense - Adjusted Taxes) / Diluted Share Count`
- `Free Cash Flow = Cash Flow from Operations - Capital Expenditures`
Cross-Sheet Dependencies
- The Segment Revenue & Gross Profit sheet feeds the top line and COGS of the Income Statement.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- The Cash Flow Statement calculates the change in cash and debt paydown, which feeds the Balance Sheet and Debt Schedule.
- The Debt Schedule calculates interest expense, which loops back to the Income Statement. To prevent circularity, interest expense should be calculated on the beginning-of-period debt balance.
- The DCF Valuation pulls operating profit and taxes from the Income Statement and capex/D&A from the Cash Flow Statement.
Sign Convention
- Revenues, assets, and equity are positive.
- Expenses (COGS, SG&A, Interest) are entered as positive numbers in their respective schedules but subtracted in the Income Statement totals.
- Liabilities are positive.
- On the Cash Flow Statement, cash inflows are positive, and cash outflows (Capex, dividends paid, debt repayment) are negative.
Things Most Likely to Go Wrong
- Intersegment Eliminations: CVS has massive intersegment revenues because Aetna pays Caremark for PBM services, and Caremark pays CVS Pharmacy for dispensing drugs. Failing to model a negative eliminations line will double-count revenue.
- MBR Sensitivity: The Medical Benefit Ratio is highly sensitive. A 50 basis point error in the MBR assumption will swing consolidated operating income by hundreds of millions of dollars.
- GAAP vs. Non-GAAP EPS: The company reports massive non-cash amortisation and impairment charges. The model must clearly bridge GAAP Net Income to Adjusted EPS, as the market values CVS entirely on the adjusted figure.
- Goodwill Impairments: The $5.7 billion impairment in 2025 severely distorts historical margin analysis. This must be excluded from go-forward run-rate calculations.
- Share Count Dynamics: The company paused share repurchases in 2024 and 2025. Do not assume a historical buyback run-rate; share count should remain flat or grow slightly due to stock-based compensation.
- Working Capital Cash Flow: Because CVS operates with negative net working capital, revenue declines actually consume cash as payables shrink faster than receivables.
- CostVantage Transition: The 2025 shift to the CostVantage pricing model alters the gross margin profile of the Pharmacy & Consumer Wellness segment. Historical margin percentages for this segment are not perfectly indicative of future performance.
- Medicare Advantage Star Ratings: These ratings impact revenue yields with a one-to-two year lag. The model must account for the delayed impact of rating upgrades or downgrades on Aetna's premium yields.
Validation Checks
- "Consolidated Total Revenue should equal the sum of the three segments minus Intersegment Eliminations (which typically run at negative 10% to 12% of gross combined segment revenues)."
- "The Medical Benefit Ratio (MBR) must remain between 85.0% and 89.0%; flag if outside this band."
- "Capex as a percentage of revenue should not exceed 1.0%."
- "Operating Cash Flow should be consistently higher than GAAP Net Income due to heavy D&A and impairment add-backs."
- "The Balance Sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Adjusted Effective Tax Rate should be approximately 25.0% to 26.0%."
- "Dividend payout ratio should remain between 35% and 45% of Adjusted EPS."
- "Debt/EBITDA should trend towards the company's 3.0x target; flag if it exceeds 4.0x."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Health Care Benefits Revenue Growth | 8.0 | % | Reflects continued Medicare Advantage and individual exchange growth, normalising from recent spikes. |
| Health Services Revenue Growth | 5.0 | % | Driven by specialty pharmacy growth, offset by PBM pricing pressures. |
| Pharmacy & Consumer Wellness Growth | 3.5 | % | Based on management's 2025 guidance for script growth and retail stabilisation. |
| Intersegment Eliminations | -11.5 | % of Gross Rev | Historical average of internal revenue transfers between Aetna, Caremark, and Retail. |
| Medical Benefit Ratio (MBR) | 88.0 | % | Reflects elevated Medicare Advantage utilisation trends observed in 2024 and 2025. |
| SG&A as % of Revenue | 10.5 | % | Historical average, accounting for recent corporate cost-cutting initiatives. |
| Capital Expenditures | 3,100 | $ Millions | Aligns with management's 2026 guidance of $3.0 to $3.2 billion. |
| Adjusted Effective Tax Rate | 25.3 | % | Management guidance for 2026. |
| Annual Dividend per Share | 2.66 | $ | Current annualised dividend rate, expected to be maintained. |
| Diluted Share Count | 1,271 | Millions | Management's 2025 guidance, reflecting a pause in share repurchases. |
| Weighted Average Interest Rate | 4.5 | % | Based on the current blended yield of the company's senior notes. |
| WACC | 7.5 | % | Standard discount rate for a diversified, large-cap healthcare services firm. |
| Terminal Growth Rate | 1.5 | % | Conservative long-term growth assumption for a mature healthcare business. |
Data Sources & Benchmarks
- Filings: SEC EDGAR (CVS Health 10-K, 10-Q, 8-K), CVS Health Investor Relations website.
- Key Peers: UnitedHealth Group (UNH), Cigna (CI), Elevance Health (ELV), Walgreens Boots Alliance (WBA).
- Industry Data: Centers for Medicare & Medicaid Services (CMS) for Medicare Advantage enrollment and Star Ratings data.
- Consensus Estimates: FactSet or Bloomberg for forward-looking Adjusted EPS and revenue consensus.
- Proprietary Data: IQVIA for national prescription dispensing volumes and specialty drug pricing trends.
Sources
- CVS Health Corporation Q4 and Full-Year 2025 Earnings Release (February 10, 2026)
- CVS Health Corporation Q4 and Full-Year 2024 Earnings Release (February 12, 2025)
- CVS Health Corporation 2025 Form 10-K
- CVS Health Corporation 2024 Form 10-K
- CVS Health Investor Relations Presentations and Guidance Transcripts (2025-2026)
Do more with the CVS Health model
Frequently asked
What is CVS Health's business model?+
CVS Health is a vertically integrated health solutions company that operates across the entire healthcare spectrum. It provides health insurance, pharmacy benefit management, and retail pharmacy services, aiming to control healthcare costs and improve patient outcomes.
How does CVS Health generate revenue across its segments?+
CVS Health generates revenue through three main segments: Health Services (PBM and healthcare delivery), Health Care Benefits (Aetna insurance products), and Pharmacy & Consumer Wellness (retail pharmacy and general merchandise sales). This integrated approach allows the company to direct patients through its owned assets for comprehensive care.
What are the key capital expenditure assumptions for CVS Health's financial model?+
The financial model assumes CVS Health's capital expenditure as a percentage of revenue is approximately 0.88%. This reflects a relatively asset-light business model, with capex split between maintenance for existing operations and growth investments in primary care expansion and digital platforms.
What is the primary purpose of the CVS Health financial model?+
The model evaluates CVS Health's sum-of-the-parts equity valuation to determine whether the turnaround in Medicare Advantage margins and the stabilization of the retail pharmacy footprint can offset pharmacy benefit manager pricing pressures. Its goal is to assess if these factors can drive sustainable free cash flow generation.
Can I download an Excel financial model for CVS Health?+
Yes, an Excel financial model for CVS Health is available for download. This model provides a forecast horizon from FY2026 to FY2030, allowing users to analyze future financial performance and key assumptions.
How does CVS Health manage its working capital?+
CVS Health operates with negative net working capital, typically ranging from negative 2% to negative 4% of revenue. This is primarily achieved by funding growth through high payables to drug manufacturers and deferred premium revenue from its insurance segment.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Health Insurance Company Financial Models
Browse another company in the same sector.
Cigna
The Cigna Group is a global health company that operates a massive pharmacy benefit manager (PBM) and a major commercial health insurance business.
Centene
Centene Corporation is a leading managed care organisation (MCO) focused primarily on government-sponsored healthcare programmes, serving uninsured and under-insured individuals.
Elevance Health
Elevance Health (formerly Anthem) is one of the largest managed healthcare companies in the United States, serving approximately 45.2 million medical members as of December 2025.
Humana
Humana is a managed healthcare company in the United States focused on government-sponsored programmes, particularly Medicare Advantage, operating as both a health insurance risk-bearing entity and a direct provider of healthcare services.
UnitedHealth Group
UnitedHealth Group is a diversified health care company operating through two distinct but complementary platforms: UnitedHealthcare (health benefits) and Optum (health services).
Explore more Healthcare financial model templates.
